Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GAMIDA CELL LTD.

(GMDA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Gamida Cell: Q3 Earnings Snapshot

11/15/2021 | 07:37am EST

JERUSALEM (AP) _ Gamida Cell Ltd. (GMDA) on Monday reported a loss of $19.6 million in its third quarter.

On a per-share basis, the Jerusalem-based company said it had a loss of 33 cents.

The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 45 cents per share.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on GMDA at https://www.zacks.com/ap/GMDA

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News

All news about GAMIDA CELL LTD.
07:56aGamida Cell Plans Rolling Submission of Biologics License Application for Bone Marrow T..
MT
07:28aGamida Cell to Begin Biologics License Application Submission for Omidubicel
DJ
07:12aGAMIDA CELL : Provides Update on Omidubicel BLA Submission - Form 8-K
PU
07:04aGamida Cell Provides Update on Omidubicel BLA Submission
BU
07:03aGAMIDA CELL LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/13GAMIDA CELL : Amendment to Initial Statement of Beneficial Ownership (Form 3/A)
PU
01/07Gamida Cell Announces Data to be Presented at 2022 Transplantation & Cellular Therapy M..
BU
01/03GAMIDA CELL LTD. : Regulation FD Disclosure (form 8-K)
AQ
2021AML Hub increases congress coverage to provide latest developments in acute myeloid leu..
AQ
2021Gamida Cell Presents Two-Year Survival Data for GDA-201 and Resource Utilization Analys..
BU
More news
Analyst Recommendations on GAMIDA CELL LTD.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -84,0 M - -
Net cash 2021 21,2 M - -
P/E ratio 2021 -1,89x
Yield 2021 -
Capitalization 161 M 161 M -
EV / Sales 2021 -
EV / Sales 2022 88,0x
Nbr of Employees 111
Free-Float -
Chart GAMIDA CELL LTD.
Duration : Period :
Gamida Cell Ltd. Technical Analysis Chart | GMDA | IL0011552663 | MarketScreener
Technical analysis trends GAMIDA CELL LTD.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 2,72 $
Average target price 15,00 $
Spread / Average Target 451%
EPS Revisions
Managers and Directors
Julian Adams Chief Executive Officer & Director
Shai Lankry Chief Financial Officer
Robert I. Blum Chairman
Ronit Simantov Chief Medical Officer
Tracey Lodie Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
GAMIDA CELL LTD.7.09%132
GILEAD SCIENCES, INC.-3.00%88 346
REGENERON PHARMACEUTICALS-3.21%63 906
VERTEX PHARMACEUTICALS5.22%58 750
WUXI APPTEC CO., LTD.-5.55%54 178
BIONTECH SE-34.36%40 873